Cerebrolysin: A Brain Extract, Not a Defined Molecule

Cerebrolysin is not a single compound. It is a preparation of low-molecular-weight peptides and amino acids produced by enzymatic breakdown of purified porcine brain protein — a mixture, supplied as a solution rather than a lyophilised powder.

That distinguishes it from everything else on this site, and it is the fact that shapes how its evidence should be read.

Why "a mixture" matters

For a defined molecule, purity has a clear meaning: how much of the sample is the target compound, verifiable by HPLC and mass spectrometry. The COA guide sets out how that works.

For a biological extract, that framework does not apply cleanly:

• There is no single target peak to integrate against — the product is a distribution of fragments.

• Batch consistency depends on process control rather than on synthesising one molecule correctly.

• "Purity 99%" is close to meaningless for a mixture, yet it appears on listings anyway.

• The source is animal tissue, which introduces considerations synthetic peptides do not have.

What the clinical evidence covers

Cerebrolysin has a substantial trial literature, concentrated on acute ischaemic stroke, traumatic brain injury, and vascular dementia. It is used adjunctively in some countries — alongside standard care such as thrombectomy rather than instead of it.

The literature is genuinely mixed. Some trials and meta-analyses report benefit on functional outcome scales; others do not, and methodological criticism has been raised about parts of the evidence base. It is neither dismissible nor established.

Route and presentation

Cerebrolysin is supplied as a ready-made solution in ampoules, typically administered intravenously or intramuscularly in clinical use — often as an infusion rather than a simple injection.

That means none of the reconstitution arithmetic applies: there is no powder, no diluent choice, and no concentration to calculate. It also means the subcutaneous self-administration described in non-clinical settings differs from how it was studied.

Frequently asked questions

Is cerebrolysin a peptide?

It is a mixture containing peptides, rather than a peptide. That distinction matters for how purity, dosing, and batch consistency can be assessed at all.

Why is it not approved in the US?

It has not been through the FDA approval process. Approval elsewhere reflects different regulatory frameworks and evidence standards, as with thymosin alpha-1.

Can its purity be verified?

Not in the way a synthetic peptide’s can. For a biological extract the relevant assurance is manufacturing process control, which a buyer outside the regulated channel has no way to inspect.